ImmunicIMUX
IMUX
About: Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Employees: 91
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
104% more call options, than puts
Call options by funds: $859K | Put options by funds: $421K
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
25% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 16
6% more funds holding
Funds holding: 62 [Q3] → 66 (+4) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
5.45% less ownership
Funds ownership: 62.16% [Q3] → 56.7% (-5.45%) [Q4]
45% less capital invested
Capital invested by funds: $92.4M [Q3] → $51.1M (-$41.3M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
506%
upside
Avg. target
$11
1,011%
upside
High target
$17
1,617%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 28% 1-year accuracy 107 / 376 met price target | 1,617%upside $17 | Buy Maintained | 30 Apr 2025 |
B. Riley Securities William Woods 25% 1-year accuracy 1 / 4 met price target | 506%upside $6 | Buy Reiterated | 16 Apr 2025 |
HC Wainwright & Co. Matthew Caufield 25% 1-year accuracy 17 / 68 met price target | 910%upside $10 | Buy Reiterated | 15 Apr 2025 |
Financial journalist opinion
Based on 7 articles about IMUX published over the past 30 days
Positive
Proactive Investors
11 hours ago
Immunic reports reduced disability worsening in progressive multiple sclerosis trial
Immunic Inc (NASDAQ:IMUX) has reported promising results from its Phase 2 CALLIPER trial of vidofludimus calcium, which showed a 30% reduction in the risk of 24-week confirmed disability worsening in patients with primary progressive multiple sclerosis (PPMS) compared to placebo. The study enrolled 467 patients with progressive multiple sclerosis (PMS), including subpopulations with PPMS and non-active secondary progressive multiple sclerosis.
Neutral
PRNewsWire
13 hours ago
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis – – Showed Consistent Reduction of Disability Worsening in Subpopulations Without Inflammatory Lesions at Baseline in Overall Study Population; Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events in Patients Without Gadolinium-Enhancing Lesions at Baseline by 29% Compared to Placebo – – Reduced Annualized Rate of Thalamic Brain Volume Loss by 20% Compared to Placebo – – Confirmed Favorable Safety and Tolerability Observed in Previous Clinical Trials; No New Safety Signals Identified – – Webcast to be Held Today, April 30, at 8:00 am ET – NEW YORK , April 30, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). Clinical Endpoints In the overall PMS patient population (n=467), vidofludimus calcium reduced the relative risk of 24-week confirmed disability worsening (24wCDW) events based on changes in the expanded disability status scale (EDSS) by 20% compared to placebo.
Positive
Seeking Alpha
2 days ago
Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher
Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and recent stock dilution, Immunic's market cap remains low, suggesting significant upside if clinical trials succeed. Vidofludimus calcium's unique dual action offers neuroprotection and anti-inflammatory benefits, positioning it as a potential next-gen oral MS treatment.
Neutral
PRNewsWire
2 weeks ago
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
NEW YORK , April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its previously announced registered direct offering of 5,666,667 shares of its common stock at a price of $0.90 per share, led by Aberdeen Investments. All securities in the offering were sold by Immunic.
Neutral
Proactive Investors
3 weeks ago
Immunic announces pricing of $5.1M direct offering to support clinical pipeline
Immunic Inc (NASDAQ:IMUX) has priced its $5.1 million registered direct offering led by Aberdeen Investments, selling 5.67 million shares at $0.90 each. The biotechnology company, which is advancing orally administered therapies for chronic inflammatory and autoimmune diseases, expects the financing to close around April 10.
Neutral
PRNewsWire
3 weeks ago
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
NEW YORK , April 9, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of a registered direct offering of 5,666,667 shares of its common stock at the market under Nasdaq rules at a price of $0.90 per share, led by Aberdeen Investments. All securities in the offering are being sold by Immunic.
Neutral
PRNewsWire
4 weeks ago
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
NEW YORK , April 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in April: April 5-9: American Academy of Neurology (AAN) 2025 Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in San Diego, California.
Positive
Proactive Investors
1 month ago
Immunic provides MS research update – ICYMI
Immunic Inc (NASDAQ:IMUX) earlier this week provided an update on its multiple sclerosis (MS) drug, vidofludimus calcium, highlighting its potential to address both inflammation and neuroprotection. Dr Hella Kohlhof, Immunic's Chief Scientific Officer, explained that the drug works through a dual mode of action—activating Nurr1 for neuroprotection and inhibiting DHODH to reduce inflammation and Epstein-Barr virus reactivation.
Neutral
PRNewsWire
1 month ago
Immunic to Participate in Scientific and Investor Conferences in March
NEW YORK , March 3, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March: March 4-7: 34th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract talk presentations at this conference in Hamburg, Germany.
Positive
Proactive Investors
2 months ago
Biotechs challenge big pharma with new oral weight loss therapies
With the smash success of glucagon-like peptide-1 (GLP-1) agonists as a treatment for obesity, pharmaceutical giants and emerging biotechnology firms alike are working to develop an equally effective option in the form of pills. The weight loss drug market, projected by Goldman Sachs to reach $130 billion by 2030, represents a significant opportunity for drugmakers.
Charts implemented using Lightweight Charts™